Pictet Asset Management (UK)’s Esperion Therapeutics ESPR Stock Holding History

Pictet Asset Management (UK)’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$2.79M	Buy	131,849 +2,460	+2%	+$59.2K	﹤0.01%	960
2021 Q1	$3.63M	Buy	129,389 +6,712	+5%	+$198K	﹤0.01%	898
2020 Q4	$3.19M	Sell	122,677 -4,000	-3%	-$120K	﹤0.01%	902
2020 Q3	$4.71M	Buy	126,677 +15,293	+14%	+$606K	0.01%	738
2020 Q2	$5.71M	Buy	111,384 +7,576	+7%	+$317K	0.01%	648
2020 Q1	$3.27M	Buy	103,808 +42,100	+68%	+$2.22M	0.01%	751
2019 Q4	$3.68M	Buy	+61,708	New	+$2.77M	0.01%	829
2019 Q2	–	Sell	-437,518	Closed	-$17.6M	–	1026
2019 Q1	$17.6M	Buy	437,518 +52,467	+14%	+$2.35M	0.04%	430
2018 Q4	$17.7M	Sell	385,051 -7,262	-2%	-$350K	0.04%	398
2018 Q3	$17.4M	Buy	392,313 +46,642	+13%	+$2.14M	0.04%	442
2018 Q2	$13.5M	Buy	345,671 +57,117	+20%	+$2.89M	0.03%	451
2018 Q1	$20.9M	Sell	288,554 -54,839	-16%	-$4.03M	0.05%	372
2017 Q4	$22.6M	Buy	343,393 +36,938	+12%	+$1.99M	0.06%	363
2017 Q3	$15.4M	Buy	306,455 +33,574	+12%	+$1.62M	0.04%	413
2017 Q2	$8.74M	Buy	272,881 +144,339	+112%	+$5.31M	0.03%	495
2017 Q1	$4.54M	Buy	+128,542	New	+$2.94M	0.01%	636

Other funds holding ESPR

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Pictet Asset Management (UK)'s ESPR Position: Q2 2021 in Review

Pictet Asset Management (UK) increased its Esperion Therapeutics (ESPR) stake by 1.9% in Q2 2021, buying an estimated $59.2K and bringing the position to 131,849 shares worth $2.79M. The position accounts for ﹤0.01% of the portfolio, ranked #960.

Pictet Asset Management (UK) first reported a position in ESPR in Q1 2017 and has held it in 16 quarters since. The position peaked at $22.6M in Q4 2017. 142 funds tracked by Wall St. Rank hold ESPR as of Q2 2021.

Pictet Asset Management (UK) held 131,849 shares of Esperion Therapeutics worth $2.79M as of Q2 2021.
Pictet Asset Management (UK) bought 2,460 Esperion Therapeutics shares in Q2 2021, an estimated $59.2K.
Esperion Therapeutics made up ﹤0.01% of Pictet Asset Management (UK)'s portfolio in Q2 2021, its #960 holding.
Pictet Asset Management (UK) first reported a position in Esperion Therapeutics in Q1 2017 and has held it in 16 quarters since.
Pictet Asset Management (UK)'s Esperion Therapeutics position peaked at $22.6M in Q4 2017.
142 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2021.

Based on Pictet Asset Management (UK)'s 13F filing for Q2 2021, filed 16 Aug 2021.